These findings nominate <i>ACSL4</i>-driven ferroptosis susceptibility as a lineage-specific vulnerability rendering monocytic AML selectively sensitive to SRC-directed therapy while resistant to BCL2 inhibition. This evidence concerns the gene ACSL4 and acute myeloid leukemia.